Close

Please select at least one article in order to proceed.

Ok

March 25, 2023

Position Statement on the management of the immune checkpoint inhibitor induced colitis via multidisciplinary modified Delphi consensus

  • Valérie Desmedt,
  • Aranzazu Jauregui-Amezaga,
  • Liselotte Fierens,
  • ...
  • Joris Dutré,
  • Triana Lobatón
  • for BIRD (Belgian IBD Research and Development), Belgian Society of Medical Oncology (BSMO), Belgian group of Digestive Oncology (BGDO), and BeRS (Belgian Respiratory Society)
Published online: March 25, 2023

March 24, 2023

Neoadjuvant Chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-Related Quality of Life longitudinal analysis

  • Caroline Bascoul-Mollevi,
  • Sophie Gourgou,
  • Christophe Borg,
  • ...
  • Beata Juzyna,
  • Florence Castan,
  • Thierry Conroy
Published online: March 24, 2023

Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data

  • Alice Boilève,
  • Matthieu Faron,
  • Sarah Fodil-Cherif,
  • ...
  • Antoine Italiano,
  • Eric Baudin,
  • Julien Hadoux
Published online: March 24, 2023

SURVIVAL IN MELANOMA IN THE NORDIC COUNTRIES INTO THE ERA OF TARGETED AND IMMUNOLOGICAL THERAPIES

  • Filip Tichanek,
  • Asta Försti,
  • Akseli Hemminki,
  • Otto Hemminki,
  • Kari Hemminki
Published online: March 24, 2023
Open Access

March 23, 2023

SURGEON PROFICIENCY GAIN AND SURVIVAL AFTER GASTRECTOMY FOR GASTRIC ADENOCARCINOMA: A POPULATION-BASED COHORT STUDY

  • Johannes Asplund,
  • Hugh Mackenzie,
  • Sheraz R. Markar,
  • Jesper Lagergren
Published online: March 23, 2023
Open Access

The ethics of risk-stratified cancer screening

  • Rebecca A Dennison,
  • Juliet A Usher-Smith,
  • Stephen D John
Published online: March 23, 2023

Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup

  • Marco Rubatto,
  • Paolo Fava,
  • Ignazio Stanganelli,
  • ...
  • Mario Mandalà,
  • Michele Guida,
  • Pietro Quaglino
Published online: March 23, 2023

Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: results of a prospective phase II trial (BEVABEL- GETUG/AFU24)11Previous presentation: ESMO 2020

  • Constance Thibault,
  • Aude Fléchon,
  • Laurence Albiges,
  • ...
  • Aurélien de Reyniès,
  • Yves Allory,
  • Stéphane Oudard
Published online: March 23, 2023

Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice

  • Domenica Lorusso,
  • Nicoletta Colombo,
  • Antonio Casado Herraez,
  • ...
  • Jodi McKenzie,
  • Vimalanand S. Prabhu,
  • Vicky Makker
Published online: March 23, 2023
Open Access

March 22, 2023

BACK TO THE FUTURE: THE IMPACT OF ESTROGEN RECEPTOR PROFILE IN THE ERA OF MOLECULAR ENDOMETRIAL CANCER CLASSIFICATION11Presentation: October 2022 at ESGO (European Society of Gynaecological Oncology) congress

  • Emanuele Perrone,
  • Ilaria Capasso,
  • Francesca De Felice,
  • ...
  • Gian Franco Zannoni,
  • Scambia Giovanni,
  • Fanfani Francesco
Published online: March 22, 2023

Efficacy and tolerability of sorafenib in Desmoid type fibromatosis: a need to review dose

  • Vikas Garg,
  • B. Bharath,
  • Sameer Rastogi,
  • ...
  • Adarsh Barwad,
  • Ekta Dhamija,
  • Shivanand Gamangatti
Published online: March 22, 2023

Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial11Prior presentation/report: Results from an earlier database lock were presented at the Society for Melanoma Research (SMR), 18th International Congress, October 28–31, 2021, and by Tawbi HA, et al. (N Engl J Med. 2022;386:24–34).,22Trial registration: ClinicalTrials.gov (NCT03470922)

  • Dirk Schadendorf,
  • Hussein Tawbi,
  • Evan J. Lipson,
  • ...
  • Ling Shi,
  • Sarah Keidel,
  • Georgina V. Long
Published online: March 22, 2023
Open Access

March 21, 2023

Corrigendum to ‘Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry’ [Eur J Cancer 180 (2023) 71–84]

  • Jonas Ecker,
  • Florian Selt,
  • Dominik Sturm,
  • ...
  • Stefan M. Pfister,
  • Olaf Witt,
  • Till Milde
Published online: March 21, 2023

March 20, 2023

Defining the role of real-world data in cancer clinical research: the position of the European Organisation for Research and Treatment of Cancer

  • Robbe Saesen,
  • Mieke Van Hemelrijck,
  • Jan Bogaerts,
  • ...
  • Roger Wilson,
  • Denis Lacombe,
  • Winette T. van der Graaf
Published online: March 20, 2023
Open Access

March 17, 2023

Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials

  • Runcong Nie,
  • Foping Chen,
  • Mariano Provencio,
  • ...
  • Yuanfang Li,
  • Sacha I. Rothschild,
  • Muyan Cai
Published online: March 17, 2023
Open Access

Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?

  • Alexander HR Varey,
  • John F Thompson,
  • Julie R Howle,
  • Serigne N Lo,
  • Sydney Ch’ng,
  • Matteo S Carlino
Published online: March 17, 2023

March 16, 2023

Electrochemotherapy in radiotherapy-resistant epidural spinal cord compression in metastatic cancer patients

  • Frederic Deschamps,
  • Lambros Tselikas,
  • Steven Yevich,
  • ...
  • Amelie Gaudin,
  • Lluis M. Mir,
  • Thierry de Baere
Published online: March 16, 2023
Open Access

Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable esophageal squamous cell carcinoma

  • Honglei Wang,
  • Zeying Jiang,
  • Qihua Wang,
  • ...
  • Shuling Chen,
  • Chao Cheng,
  • Wenfang Chen
Published online: March 16, 2023
Open Access

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent hematological malignancies

  • O. Van Not,
  • A.J.M. van den Eertwegh,
  • J.B. Haanen,
  • ...
  • M.W.J.M. Wouters,
  • K.P.M. Suijkerbuijk,
  • W.A.M. Blokx
Published online: March 16, 2023
Open Access

March 15, 2023

Local recurrence in primary localized resected gastro-intestinal stromal tumors A registry observational national cohort study including 912 patients

  • Roos.F. Bleckman,
  • Evelyne Roets,
  • Nikki S. IJzerman,
  • ...
  • Neeltje Steeghs,
  • Anna K.L. Reyners,
  • Boudewijn van Etten
Published online: March 15, 2023
Open Access

March 10, 2023

Corrigendum to ‘Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study’ [Eur J Cancer 171 (2022) 183–192]

  • Fabio Conforti,
  • Alessandro Gronchi,
  • Nicholas Penel,
  • ...
  • David da Silva Moura,
  • Nadia H. Muñiz,
  • Tommaso De Pas
Published online: March 10, 2023

Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma

  • Julia Lai-Kwon,
  • Sarah Jacques,
  • Matteo Carlino,
  • ...
  • Serigne N. Lo,
  • Alexander M. Menzies,
  • Georgina V. Long
Published online: March 10, 2023

Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198)

  • Walid L. Shaib,
  • Rupji Manali,
  • Yuan Liu,
  • ...
  • Erwin Robin,
  • Timothy Huyck,
  • Tanios Bekaii-Saab
Published online: March 10, 2023

March 9, 2023

Duty to recontact in genomic cancer care: A tool helping to assess the professional’s responsibility

  • Martine C. Ploem,
  • Noor A.A. Giesbertz,
  • Annelien L. Bredenoord,
  • Valesca P. Retèl,
  • Wim H. van Harten
Published online: March 09, 2023
Open Access

March 7, 2023

Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials

  • Ivan Caramanna,
  • Jaap C. Reijneveld,
  • Peter M. van de Ven,
  • ...
  • Andrew Bottomley,
  • Martin Klein
  • on behalf of the EORTC Quality of Life Group and EORTC Brain Tumor Group
Published online: March 07, 2023

Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose–response meta-analysis

  • Lun-Jie Yan,
  • Long-Shan Yang,
  • Yu-Chuan Yan,
  • ...
  • Dong-Xu Wang,
  • Zhao-Ru Dong,
  • Tao Li
Published online: March 07, 2023

Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases

  • Pamela T. Aliaga,
  • Josè Sandoval,
  • Dario Trapani,
  • ...
  • Angela Esposito,
  • Carmen Criscitiello,
  • Giuseppe Curigliano
Published online: March 07, 2023

Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial

  • Luca Malorni,
  • Giampaolo Bianchini,
  • Roberta Caputo,
  • ...
  • Mariacristina Di Marino,
  • Grazia Arpino,
  • Michelino De Laurentiis
Published online: March 07, 2023

Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery

  • Lisanne.P. Zijlker,
  • Stijn J.C. van der Burg,
  • Christian U. Blank,
  • ...
  • Michel W.M.J. Wouters,
  • Winan J. van Houdt,
  • Alexander C.J. van Akkooi
Published online: March 07, 2023

Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial1

  • Renu R. Bahadoer,
  • Geke A.P. Hospers,
  • Corrie A.M. Marijnen,
  • ...
  • Bengt Glimelius,
  • Cornelis J.H. van de Velde
  • collaborative investigators
Published online: March 07, 2023
Open Access

March 6, 2023

Urinary volatile organic compounds for colorectal cancer screening: A systematic review and meta-analysis

  • Elsa L.S.A. van Liere,
  • Laura J. van Dijk,
  • Sofie Bosch,
  • ...
  • Tim G.J. de Meij,
  • Dewkoemar Ramsoekh,
  • Nanne K.H. de Boer
Published online: March 06, 2023
Open Access

March 3, 2023

Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers

  • Rebeca Lozano,
  • Elena Castro,
  • Fernando Lopez-Campos,
  • ...
  • José Rubio-Briones,
  • Shahneen Sandhu,
  • David Olmos
Published online: March 03, 2023

March 2, 2023

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

  • Silke Gillessen,
  • Alberto Bossi,
  • Ian D. Davis,
  • ...
  • Almudena Zapatero,
  • Thomas Zilli,
  • Aurelius Omlin
Published online: March 02, 2023

February 27, 2023

Corrigendum to “Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma” [Eur J Cancer 126 (2020) 93–103]

  • Didier Decaudin,
  • Estelle Frisch Dit Leitz,
  • Fariba Nemati,
  • ...
  • Aart Jochemsen,
  • Sergio Roman-Roman,
  • Samar Alsafadi
Published online: February 27, 2023
Open Access

February 24, 2023

CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma

  • Laurens S. ter Maat,
  • Isabella A.J. van Duin,
  • Sjoerd G. Elias,
  • ...
  • Pim A. de Jong,
  • Karijn P.M. Suijkerbuijk,
  • Mitko Veta
Published online: February 24, 2023
Open Access

Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164

  • Dung T. Le,
  • Luis A. Diaz Jr.,
  • Tae W. Kim,
  • ...
  • Pierre Leconte,
  • Patricia Marinello,
  • Thierry André
Published online: February 24, 2023
Advertisement

The content on this site is intended for healthcare professionals.


We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


RELX